Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A

Recruiting now

Conditions studied: Hemophilia A

In brief

The investigators propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A. Per current standard of care, most patients are on prophylactic FVIII replacement therapy intravenously several times weekly with a goal of keeping the trough \>1% FVIII. Recent phase 3 data suggest superior bleed protection with emicizumab prophylaxis every 1-2 weeks. It is the purpose of this study to longitudinally assess joint health and bone density over 3 years and to compare the effect of routine factor VIII prophylaxis with emicizumab prophylaxis.

Key facts

Study ID

NCT04131036

Run by

Washington Institute for Coagulation

People needed

40

Starts

2019-04-04

Expected to finish

2026-08-01

Last updated by the study team

2023-09-05

Who can join

Age: 16 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male gender
• Severe hemophilia A (factor VIII < 1%)
• Age ≥ 16 year
• Either on prophylaxis with factor VIII or emicizumab with the intention to stay on the current regimen for the next 3 years
• Willing and able to give written informed consent/assent
• Willing to undergo MSKUS, DEXA scan +/- collection of blood sampling for repository biomarkers
• Willing to come in for baseline and 3 yearly visits
• Willing to answer phone survey for bleeding and safety every 3 months

You may not qualify if…

• Current FVIII inhibitor of > 0.6 BU
• Unable to take FVIII replacement
• Other known bleeding disorder
• Other rheumatologic disorder affecting joints
• Other known neuromotor defect (making physical exam difficult)

Where it is running

• Hemophilia and Thrombosis Treatment Center, University of California, San Diego — San Diego, California, United States (enrolling)
• The University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States (enrolling)
• Washington Center for Bleeding Disorders at Washington Institute for Coagulation — Seattle, Washington, United States (enrolling)
• Orthopedic Hemophilia Treatment Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.